These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34803077)

  • 1. Renin-Angiotensin-Aldosterone System Inhibitors Prevent the Onset of Oxaliplatin-Induced Peripheral Neuropathy: A Retrospective Multicenter Study and in Vitro Evaluation.
    Uchida M; Ushio S; Niimura T; Takechi K; Kawazoe H; Hidaka N; Tanaka A; Araki H; Zamami Y; Ishizawa K; Kitamura Y; Sendou T; Kawasaki H; Namba H; Shibata K; Tanaka M; Takatori S
    Biol Pharm Bull; 2022 Feb; 45(2):226-234. PubMed ID: 34803077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive Effects of Renin-angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy: A Retrospective Observational Study.
    Uchida M; Kawazoe H; Takatori S; Namba H; Uozumi R; Tanaka A; Kawasaki H; Araki H
    Clin Ther; 2018 Jul; 40(7):1214-1222.e1. PubMed ID: 29983264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
    Kang L; Tian Y; Xu S; Chen H
    J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
    Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
    BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
    Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
    Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
    Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
    Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies.
    Miyamoto T; Domoto R; Sekiguchi F; Kamaguchi R; Nishimura R; Matsuno M; Tsubota M; Fujitani M; Hatanaka S; Koizumi Y; Wang D; Nishibori M; Kawabata A
    J Pharmacol Sci; 2022 Mar; 148(3):315-325. PubMed ID: 35177211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro.
    Shigematsu N; Kawashiri T; Kobayashi D; Shimizu S; Mine K; Hiromoto S; Uchida M; Egashira N; Shimazoe T
    Sci Rep; 2020 Apr; 10(1):6734. PubMed ID: 32317735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paeoniflorin ameliorates oxaliplatin-induced peripheral neuropathy via inhibiting neuroinflammation through influence on gut microbiota.
    Xu J; Lu L; Jiang S; Qin Z; Huang J; Huang M; Jin J
    Eur J Pharmacol; 2024 May; 971():176516. PubMed ID: 38513881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
    Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
    BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.
    Chen SJ; Chen LH; Yeh YM; Lin CK; Lin PC; Huang HW; Shen MR; Lin BW; Lee JC; Lee CC; Lee YF; Chiang HC; Chang JY
    Theranostics; 2021; 11(10):4672-4687. PubMed ID: 33754020
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system.
    Coolbrandt A; Tobback H; Govaerts R; Vandezande L; Vinckx M; Laenen A; Wildiers H; Verslype C; Dekervel J; Van Herpe F; Van Cutsem E
    ESMO Open; 2023 Apr; 8(2):101205. PubMed ID: 37018872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
    Ishiguro K; Hayashi K; Sasamura H; Sakamaki Y; Itoh H
    Hypertension; 2009 Jan; 53(1):83-9. PubMed ID: 19047581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotherapy prevents peripheral neuropathy induced by oxaliplatin in mice.
    Maia JRLCB; Machado LKA; Fernandes GG; Vitorino LC; Antônio LS; Araújo SMB; Colodeti LC; Fontes-Dantas FL; Zeidler JD; Saraiva GN; Da Poian AT; Figueiredo CP; Passos GF; da Costa R
    Neuropharmacology; 2024 Mar; 245():109828. PubMed ID: 38158014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
    Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
    Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropathy.
    Warren G; Osborn M; Tsantoulas C; David-Pereira A; Cohn D; Duffy P; Ruston L; Johnson C; Bradshaw H; Kaczocha M; Ojima I; Yates A; O'Sullivan SE
    J Pain; 2024 Jul; 25(7):104470. PubMed ID: 38232863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidants Improve Oxaliplatin-Induced Peripheral Neuropathy in Tumor-Bearing Mice Model: Role of Spinal Cord Oxidative Stress and Inflammation.
    Agnes JP; Santos VWD; das Neves RN; Gonçalves RM; Delgobo M; Girardi CS; Lückemeyer DD; Ferreira MA; Macedo-Júnior SJ; Lopes SC; Spiller F; Gelain DP; Moreira JCF; Prediger RD; Ferreira J; Zanotto-Filho A
    J Pain; 2021 Aug; 22(8):996-1013. PubMed ID: 33774154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.
    Yildirim N; Cengiz M
    Support Care Cancer; 2020 Oct; 28(10):4781-4788. PubMed ID: 31974772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
    Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
    BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.